HPBCD a potential therapeutic agent for amiodarone-induced interstitial pneumonia
Alveolar epithelial type II (AT2) cells secrete pulmonary surfactant via lamellar bodies (LBs). Abnormalities in LBs are associated with pulmonary
Category: Drug delivery
Special issue: “Drug-Cyclodextrin Interactions. A Basis for New Formulations”
The journal Molecules (IF 4.411) started to collect manuscripts for special issue on ” Drug-Cyclodextrin Interactions. A Basis for New
Marinus Pharmaceuticals and Orion Corporation agree on Commercialization of SBECD-enabled Ganaxolone
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Review on cyclodextrin multicomponent complexes
Based on 109 references this paper gives an overview on how the addition of an auxiliary substance forming multicomponent complexes
CD-complexation enhances in vivo anti-fibrotic and anti-inflammatory effects of chrysin
Chrysin (CHR) is a natural flavonoid with a wide range of pharmacological activities, including hepatoprotection, but poor water solubility. By
Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries since
Are cyclodextrins safe for intravitreal injections?
Cyclodextrins are excellent excipients for various routes of administration, the ophthalmic delivery is potentially one of the most useful applications
Safety of inhaled HPBCD-formulated ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study
SARS-CoV-2 replication in cell cultures has been shown to be inhibited by ivermectin. However, ivermectin’s low aqueous solubility and bioavailability hinders
Intraoral/intranasal niclosamide/HPBCD formulation for treatment of COVID-19
A recently published patent of Union Therapeutics, Denmark (US11045434) (granted extremely rapidly by USPTO within 8 months from filing date)
Age-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies
Age-related eye disorders are chronic diseases that affect millions of people worldwide. They cause visual impairment and, in some cases,